{"id":"standard-dose-influenza-vaccine","safety":{"commonSideEffects":[{"rate":"10–30","effect":"Injection site soreness, redness, or swelling"},{"rate":"5–15","effect":"Myalgia (muscle aches)"},{"rate":"5–10","effect":"Headache"},{"rate":"5–10","effect":"Low-grade fever"},{"rate":"5–10","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2109042","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated influenza virus antigens (or live attenuated virus in some formulations) that trigger both humoral and cell-mediated immune responses. This priming of the adaptive immune system enables rapid recognition and neutralization of wild-type influenza virus upon natural exposure, reducing infection risk and disease severity.","oneSentence":"Standard-dose influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against circulating influenza virus strains.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:09:07.656Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of seasonal influenza in adults and children ≥6 months of age"}]},"trialDetails":[{"nctId":"NCT07371650","phase":"PHASE2","title":"This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza","status":"ACTIVE_NOT_RECRUITING","sponsor":"Traws Pharma, Inc.","startDate":"2025-12-15","conditions":"Influenza","enrollment":105},{"nctId":"NCT07485855","phase":"PHASE3","title":"Influenza Vaccination Strategy for Patients With Hematologic Malignancy","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-12-04","conditions":"Hematologic Neoplasms, Influenza, Immunogenicity","enrollment":60},{"nctId":"NCT07393685","phase":"","title":"Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPD","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University","startDate":"2026-08-01","conditions":"Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Influenza, Human, Virus Diseases","enrollment":300},{"nctId":"NCT06229392","phase":"PHASE1","title":"A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer","status":"WITHDRAWN","sponsor":"Rush University Medical Center","startDate":"2026-06-01","conditions":"Breast Cancer, Breast Cancer Triple Negative","enrollment":""},{"nctId":"NCT04901455","phase":"EARLY_PHASE1","title":"Responses to Live Attenuated Influenza Virus (LAIV) in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2022-10-03","conditions":"COPD","enrollment":24},{"nctId":"NCT04613206","phase":"PHASE2","title":"High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-01-11","conditions":"Immunization; Infection, Transplantation Infection, Influenza","enrollment":396},{"nctId":"NCT07351500","phase":"PHASE3","title":"Adaptive RCT of Corticosteroids for Severe Influenza Pneumonia in Adults","status":"NOT_YET_RECRUITING","sponsor":"Qingyuan Zhan","startDate":"2026-01-15","conditions":"Influenza","enrollment":496},{"nctId":"NCT06202521","phase":"PHASE2","title":"CX-4945 in Viral Community Acquired Pneumonia","status":"TERMINATED","sponsor":"Senhwa Biosciences, Inc.","startDate":"2024-03-20","conditions":"Community-acquired Pneumonia, SARS-CoV-2 -Associated Pneumonia, Influenza With Pneumonia","enrollment":45},{"nctId":"NCT04544267","phase":"PHASE3","title":"Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-09-15","conditions":"Influenza","enrollment":100},{"nctId":"NCT02872311","phase":"NA","title":"Open-Label Influenza Vaccine Evaluation","status":"COMPLETED","sponsor":"Marshfield Clinic Research Foundation","startDate":"2016-09","conditions":"Immune Response","enrollment":179},{"nctId":"NCT05215327","phase":"PHASE2","title":"High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2022-11-08","conditions":"Immunization; Infection, Transplantation Infection, Influenza","enrollment":270},{"nctId":"NCT06641180","phase":"PHASE3","title":"Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-04","conditions":"Influenza","enrollment":1180},{"nctId":"NCT06508437","phase":"PHASE4","title":"Effect of Influenza Vaccination on Global Systemic Inflammatory Markers in Patients With Stable Coronary Artery Disease","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2024-10-21","conditions":"Coronary Artery Disease, Inflammatory Response, Atherosclerosis","enrollment":47},{"nctId":"NCT03598439","phase":"PHASE4","title":"Randomized Influenza Vaccine Evaluation of Immune Response","status":"COMPLETED","sponsor":"Marshfield Clinic Research Foundation","startDate":"2018-07-30","conditions":"Influenza","enrollment":366},{"nctId":"NCT07192458","phase":"PHASE2","title":"High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2025-09-17","conditions":"Immunization; Infection|Transplantation Infection|Influenza, Influenza","enrollment":60},{"nctId":"NCT06664151","phase":"EARLY_PHASE1","title":"A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-11-26","conditions":"Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Cancer","enrollment":25},{"nctId":"NCT04537234","phase":"PHASE3","title":"Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-11-10","conditions":"Influenza (Healthy Volunteers)","enrollment":165},{"nctId":"NCT04498832","phase":"PHASE3","title":"Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-10-21","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":2100},{"nctId":"NCT04137887","phase":"PHASE3","title":"Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-11-04","conditions":"Influenza (Healthy Volunteers)","enrollment":33096},{"nctId":"NCT05517174","phase":"PHASE4","title":"A Pragmatic Randomized Trial to Evaluate the Effectiveness of High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in Older Adults","status":"COMPLETED","sponsor":"Tor Biering-Sørensen","startDate":"2022-09-22","conditions":"Influenza","enrollment":332438},{"nctId":"NCT06506812","phase":"PHASE4","title":"Pooled Analysis of Methodologically Harmonized Pragmatic Randomized Trials of High-Dose vs. Standard-Dose Influenza Vaccine Against Severe Clinical Outcomes","status":"COMPLETED","sponsor":"Tor Biering-Sørensen","startDate":"2025-05-31","conditions":"Influenza","enrollment":466320},{"nctId":"NCT04024228","phase":"PHASE3","title":"Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-10-28","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":1539},{"nctId":"NCT06507553","phase":"PHASE1","title":"Study of Influenza Vaccines Containing an Additional H3 Antigen in Healthy Adult Participants 18 to 49 Years of Age and 60 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-08-12","conditions":"Influenza, Healthy Volunteers","enrollment":400},{"nctId":"NCT05513391","phase":"PHASE3","title":"Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-11-10","conditions":"Influenza Immunization","enrollment":366},{"nctId":"NCT03315975","phase":"PHASE4","title":"Flu Vaccine Responses in the Setting of Melanoma Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2017-10-20","conditions":"Viral Vaccines","enrollment":40},{"nctId":"NCT03346772","phase":"PHASE4","title":"Study of Immune Responses to Influenza Vaccination","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2017-10-20","conditions":"Influenza Vaccination","enrollment":75},{"nctId":"NCT06141655","phase":"PHASE4","title":"HD vs SD Quadrivalent Influenza Vaccine in Adults Aged 65 to 79 Years in Galicia","status":"COMPLETED","sponsor":"Federico Martinón Torres","startDate":"2023-10-26","conditions":"Influenza","enrollment":134476},{"nctId":"NCT06361875","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-04-01","conditions":"Influenza Immunization","enrollment":910},{"nctId":"NCT05291676","phase":"PHASE2","title":"Systems Investigation of Vaccine Responses in Aging and Frailty","status":"RECRUITING","sponsor":"Yale University","startDate":"2023-11-06","conditions":"Influenza","enrollment":96},{"nctId":"NCT06744205","phase":"PHASE1, PHASE2","title":"A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2025-01-06","conditions":"Influenza, Healthy Volunteers","enrollment":1162},{"nctId":"NCT04487041","phase":"PHASE4","title":"Tfh Dysfunction in HIV and Aging","status":"RECRUITING","sponsor":"University of Miami","startDate":"2020-10-30","conditions":"Human Influenza","enrollment":400},{"nctId":"NCT06054269","phase":"PHASE3","title":"Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2022-11-04","conditions":"Influenza","enrollment":192},{"nctId":"NCT05091307","phase":"PHASE3","title":"A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2021-11-02","conditions":"COVID-19 Prevention","enrollment":861},{"nctId":"NCT05585983","phase":"PHASE4","title":"INfluenza VaccInation To Mitigate typE 1 Diabetes","status":"RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2022-12-14","conditions":"Diabetes Mellitus, Type 1","enrollment":100},{"nctId":"NCT03694392","phase":"","title":"Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2018-09-16","conditions":"Influenza, Pneumonia, Lower Respiratory Tract Infection","enrollment":2776278},{"nctId":"NCT05514002","phase":"PHASE4","title":"Comparison of Recombinant Influenza Vaccine Versus Standard Egg-Based Inactivated Influenza Vaccine in Adults 18-64 Years","status":"TERMINATED","sponsor":"Fatimah Dawood","startDate":"2022-09-13","conditions":"Influenza, Human","enrollment":3988},{"nctId":"NCT05947071","phase":"PHASE2","title":"High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-09-26","conditions":"Immunization; Infection, Transplantation Infection, Influenza","enrollment":312},{"nctId":"NCT05650554","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-12-12","conditions":"Influenza Immunization","enrollment":682},{"nctId":"NCT05624606","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-11-28","conditions":"Influenza Immunization","enrollment":682},{"nctId":"NCT03376321","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-01-03","conditions":"Influenza A","enrollment":334},{"nctId":"NCT03381196","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-01-21","conditions":"Influenza A","enrollment":553},{"nctId":"NCT05553301","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-10-03","conditions":"Influenza Immunization","enrollment":560},{"nctId":"NCT05875961","phase":"PHASE1","title":"Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2023-06-15","conditions":"Influenza, Human, Infections, Respiratory Tract Infections","enrollment":600},{"nctId":"NCT05874713","phase":"PHASE2","title":"Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2023-06-07","conditions":"Influenza, Human, Infections, Respiratory Tract Infections","enrollment":480},{"nctId":"NCT03179761","phase":"PHASE2","title":"High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients","status":"COMPLETED","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2017-10-09","conditions":"Hematopoietic Cell Transplantation","enrollment":124},{"nctId":"NCT02860039","phase":"PHASE2","title":"High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2016-09","conditions":"Hematopoietic Cell Transplantation Recipient, Malignant Neoplasm, Influenza","enrollment":170},{"nctId":"NCT02921997","phase":"PHASE2","title":"H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-11-07","conditions":"Avian Influenza, H1N1 Influenza, Influenza","enrollment":30},{"nctId":"NCT02936180","phase":"PHASE4","title":"Standard Versus High Dose Inactivated Influenza Vaccine in RA","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2016-10","conditions":"Rheumatoid Arthritis","enrollment":279},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT05028361","phase":"PHASE4","title":"Simultaneous mRNA COVID-19 and IIV4 Vaccination Study","status":"COMPLETED","sponsor":"Duke University","startDate":"2021-10-04","conditions":"Quality of Life, Injection Site Reaction, Adverse Drug Event","enrollment":348},{"nctId":"NCT03315104","phase":"PHASE2","title":"Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2017-11-17","conditions":"Influenza A H3N2, Influenza A H1N1","enrollment":65},{"nctId":"NCT04381936","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-03-19","conditions":"Severe Acute Respiratory Syndrome","enrollment":70000},{"nctId":"NCT03330132","phase":"PHASE4","title":"Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2017-10-07","conditions":"Influenza, Human","enrollment":1861},{"nctId":"NCT06125717","phase":"PHASE1","title":"Phase 1 Evaluation of H1 Influenza Vaccine Delivered by MIMIX MAP","status":"COMPLETED","sponsor":"Vaxess Technologies","startDate":"2022-07-02","conditions":"Influenza","enrollment":45},{"nctId":"NCT05045144","phase":"PHASE3","title":"A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-26","conditions":"Respiratory Syncytial Virus Infections","enrollment":1586},{"nctId":"NCT05269290","phase":"PHASE3","title":"Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections","status":"COMPLETED","sponsor":"Valenta Pharm JSC","startDate":"2021-09-23","conditions":"Influenza, Human, Acute Respiratory Infection, Common Cold","enrollment":240},{"nctId":"NCT04785794","phase":"PHASE1","title":"Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old","status":"COMPLETED","sponsor":"FluGen Inc","startDate":"2021-06-30","conditions":"Influenza Vaccine","enrollment":122},{"nctId":"NCT01248715","phase":"PHASE4","title":"Rapid Empiric Treatment With Oseltamivir Study (RETOS)","status":"COMPLETED","sponsor":"University of Louisville","startDate":"2010-11","conditions":"Influenza, Pneumonia","enrollment":1107},{"nctId":"NCT03669627","phase":"PHASE2","title":"CT18 Infant Influenza Priming Study in Vaccine Naive Infants","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2018-11-01","conditions":"Influenza","enrollment":159},{"nctId":"NCT03965195","phase":"PHASE4","title":"Recombinant Influenza Vaccination in U.S. Nursing Homes","status":"UNKNOWN","sponsor":"Insight Therapeutics, LLC","startDate":"2019-07-20","conditions":"Influenza, Influenza -Like Illness, Influenza, Human","enrollment":1989},{"nctId":"NCT04001504","phase":"PHASE3","title":"Vaccination Against Influenza to Prevent Cardiovascular Events After Acute Coronary Syndromes","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2019-07-19","conditions":"Acute Coronary Syndrome","enrollment":1801},{"nctId":"NCT05048589","phase":"PHASE2","title":"Feasibility of Randomizing Danish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-Based Setting","status":"COMPLETED","sponsor":"Tor Biering-Sørensen","startDate":"2021-10-01","conditions":"Influenza","enrollment":12551},{"nctId":"NCT05154383","phase":"PHASE4","title":"Effect of High-Dose Quadrivalent Influenza Vaccine (Efluelda®) Versus Standard-Dose (QIV-SD), in Subjects 65 Years of Age and Older on Innate Immunity, Including Gene Expression","status":"COMPLETED","sponsor":"Centre Hospitalier Annecy Genevois","startDate":"2021-11-15","conditions":"Vaccine Reaction","enrollment":60},{"nctId":"NCT01808456","phase":"PHASE4","title":"Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.","status":"COMPLETED","sponsor":"Inova Health Care Services","startDate":"2013-10","conditions":"Influenza, Human, Transplantation Infection","enrollment":62},{"nctId":"NCT04077424","phase":"PHASE4","title":"Senescent Immunity in Elders and Vaccine Responses (SILVER)","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2019-10-21","conditions":"Flu Vaccine","enrollment":10},{"nctId":"NCT04460781","phase":"","title":"Surveillance Study to Assess the Safety of Flublok Quadrivalent (Influenza Vaccine) in Pregnant Women and Their Offspring","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-09-17","conditions":"Influenza","enrollment":96175},{"nctId":"NCT03233217","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Patients ≥65 Years","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2017-09-15","conditions":"Influenza","enrollment":175},{"nctId":"NCT03277703","phase":"PHASE2","title":"Flu Vaccine Response in Patients on Biologic Therapies","status":"COMPLETED","sponsor":"Stony Brook University","startDate":"2017-11-03","conditions":"Rheumatologic Disorder, Inflammatory Bowel Diseases, Immune Complex Diseases","enrollment":30},{"nctId":"NCT02787044","phase":"PHASE4","title":"INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2016-08-01","conditions":"Heart Failure, Myocardial Infarction","enrollment":5388},{"nctId":"NCT05070494","phase":"PHASE4","title":"Efficacy of Different Doses of Influenza Vaccine in Chronic Hemodialysis Patients","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2021-03-01","conditions":"ESRD, Influenza Vaccine, Seroprotection","enrollment":175},{"nctId":"NCT02544880","phase":"PHASE1","title":"PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC","status":"COMPLETED","sponsor":"Donald T. Weed, MD, FACS","startDate":"2016-04-25","conditions":"Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer","enrollment":16},{"nctId":"NCT02268500","phase":"PHASE4","title":"VAccination to Improve Clinical outComes in Heart Failure Trial: a Feasibility Study (VACC-HeFT)","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2014-09","conditions":"Chronic Heart Failure","enrollment":48},{"nctId":"NCT03360851","phase":"NA","title":"DiagNostic Study of Low-dose CT and multipleX PCR on Antibiotic Treatment and Outcome of Community-Acquired Pneumonia","status":"TERMINATED","sponsor":"MJM Bonten","startDate":"2017-11-27","conditions":"Community-acquired Pneumonia","enrollment":3555},{"nctId":"NCT00987350","phase":"PHASE4","title":"Safety Study of Seasonal Influenza Vaccine by Jet Injection","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2010-01","conditions":"Healthy Adults","enrollment":60},{"nctId":"NCT03684044","phase":"PHASE3","title":"Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-01-08","conditions":"Influenza","enrollment":363},{"nctId":"NCT03699839","phase":"PHASE2, PHASE3","title":"Reducing the Burden of Influenza After Solid-Organ Transplantation","status":"COMPLETED","sponsor":"Oriol Manuel","startDate":"2018-10-26","conditions":"Influenza, Organ Transplantation","enrollment":619},{"nctId":"NCT02927431","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With Influenza","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2017-01-19","conditions":"Virus Diseases","enrollment":10},{"nctId":"NCT03845231","phase":"PHASE2","title":"Mucosal and Systemic Immunity After Viral Challenge of Healthy Volunteers Vaccinated With Inactivated Influenza Vaccine Via the Intranasal Versus Intramuscular Route","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-04-29","conditions":"Influenza","enrollment":82},{"nctId":"NCT03139565","phase":"PHASE3","title":"High Dose vs. Standard Influenza Vaccine in Adult SOT","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2016-10","conditions":"Influenza, Immunosuppression","enrollment":172},{"nctId":"NCT04374071","phase":"","title":"Early Short Course Corticosteroids in COVID-19","status":"COMPLETED","sponsor":"Henry Ford Health System","startDate":"2020-03-12","conditions":"COVID, Pneumonia, Viral","enrollment":250},{"nctId":"NCT03056924","phase":"","title":"Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2017-07-05","conditions":"Inflammatory Bowel Diseases","enrollment":173},{"nctId":"NCT02554188","phase":"PHASE2","title":"Fasting-mimicking Diet and Immunosenescence","status":"WITHDRAWN","sponsor":"University of Southern California","startDate":"2019-05-01","conditions":"Immunosenescence","enrollment":""},{"nctId":"NCT01573312","phase":"PHASE1","title":"H5N1 Vaccination With and Without AS03: Systems Biology Analysis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-05-24","conditions":"Influenza","enrollment":20},{"nctId":"NCT04122222","phase":"NA","title":"Immune Response to Influenza Vaccine in ESRD Patients","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2016-08-25","conditions":"Immunology, Nephrology","enrollment":60},{"nctId":"NCT02461758","phase":"PHASE4","title":"Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2016-10","conditions":"Inflammatory Bowel Disease (IBD)","enrollment":81},{"nctId":"NCT00844155","phase":"NA","title":"Study of the Relative Oral Bioavailability of the Antiflu Medicine Oseltamivir in the Intensive Care Unit","status":"WITHDRAWN","sponsor":"University of Manitoba","startDate":"2009-03","conditions":"Influenza A Virus Infection, Influenza B Virus Infection","enrollment":""},{"nctId":"NCT02500680","phase":"PHASE1","title":"The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101)","status":"UNKNOWN","sponsor":"Nova Immunotherapeutics Limited","startDate":"2015-07","conditions":"Influenza, Human","enrollment":102},{"nctId":"NCT03743688","phase":"","title":"Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2018-12-04","conditions":"Influenza, Influenza, Human, Vaccine Reaction","enrollment":10},{"nctId":"NCT01216332","phase":"PHASE1","title":"Standard Versus High-Dose Trivalent Inactivated Flu Vaccine in Pediatric Acute Lymphoblastic Leukemia Patients","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2010-10","conditions":"Pediatric Patients With Acute Lymphoblastic Leukemia","enrollment":50},{"nctId":"NCT03028909","phase":"PHASE2","title":"Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults Who Are Hospitalized With Type A Influenza.","status":"WITHDRAWN","sponsor":"MedImmune LLC","startDate":"2017-07-24","conditions":"Influenza - Type A Strains","enrollment":""},{"nctId":"NCT02566265","phase":"PHASE2","title":"Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients","status":"COMPLETED","sponsor":"Yale University","startDate":"2015-09","conditions":"Influenza, Multiple Myeloma, Waldenstrom's Macroglobulinemia","enrollment":122},{"nctId":"NCT00170482","phase":"","title":"Elderly Influenza Vaccine Immunogenicity Substudy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-04-25","conditions":"Influenza","enrollment":60},{"nctId":"NCT02263040","phase":"PHASE1, PHASE2","title":"A Pilot Study to Assess the Immunogenicity and Reactogenicity of High Versus Standard Dose TIV","status":"COMPLETED","sponsor":"Mount Sinai Hospital, Canada","startDate":"2014-10","conditions":"Influenza","enrollment":170},{"nctId":"NCT01715909","phase":"PHASE1","title":"A Pharmacokinetic/Pharmacodynamic Study of Oseltamivir in Immunocompromised Children With Confirmed Influenza Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01-22","conditions":"Influenza","enrollment":20},{"nctId":"NCT02297542","phase":"PHASE4","title":"Immune Response to High-Dose vs. Standard Dose Influenza Vaccine","status":"UNKNOWN","sponsor":"Health Sciences North Research Institute","startDate":"2014-10","conditions":"Elderly Immune System","enrollment":85},{"nctId":"NCT01815268","phase":"PHASE4","title":"High-Dose Influenza Vaccine in Nursing Homes","status":"UNKNOWN","sponsor":"Insight Therapeutics, LLC","startDate":"2013-02","conditions":"Influenza","enrollment":823},{"nctId":"NCT02293863","phase":"PHASE2","title":"A Study of MHAA4549A in Combination With Oseltamivir Versus Oseltamivir in Participants With Severe Influenza A Infection","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2015-01-14","conditions":"Influenza","enrollment":168},{"nctId":"NCT01720277","phase":"PHASE4","title":"High Dose Influenza Vaccine in Nursing Home - Pilot Study","status":"COMPLETED","sponsor":"Insight Therapeutics, LLC","startDate":"2012-09","conditions":"Influenza","enrollment":2957},{"nctId":"NCT02019745","phase":"","title":"Effects of Tobacco Products on Live Attenuated Influenza Virus (LAIV) Infections in Human Volunteers","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2014-06","conditions":"Influenza, Human, Smoking, Respiratory Tract Infections","enrollment":62},{"nctId":"NCT01685372","phase":"PHASE2","title":"Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2012-09","conditions":"Solid Organ Transplant Recipient (Liver, Kidney, Heart), Rheumatologic Disorder, Human Immunodeficiency Virus (HIV)","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":59,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Standard-Dose Influenza Vaccine","genericName":"Standard-Dose Influenza Vaccine","companyName":"Tor Biering-Sørensen","companyId":"tor-biering-s-rensen","modality":"Biologic","firstApprovalDate":"","aiSummary":"Standard-dose influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against circulating influenza virus strains. Used for Prevention of seasonal influenza in adults and children ≥6 months of age.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}